{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:24:24Z","timestamp":1794057864735,"version":"4.8.0"},"reference-count":196,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.prro.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:30:15Z","timestamp":1789468215000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiation Therapy for Bladder Cancer: An ASTRO Clinical Practice Guideline"],"prefix":"10.1016","author":[{"given":"Leslie K.","family":"Ballas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A.","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Comron","family":"Hassanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Zaorsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"Apolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Holzbeierlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Moroney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad R.","family":"Ritch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituraj","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine G.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bradfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0130-094X","authenticated-orcid":false,"given":"Amanda R.","family":"Helms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2026.09.001_bib0001","series-title":"Clinical Practice Guidelines We Can Trust","year":"2011"},{"key":"10.1016\/j.prro.2026.09.001_bib0002","series-title":"Finding What Works in Health Care: Standards for Systematic Reviews","year":"2011"},{"key":"10.1016\/j.prro.2026.09.001_bib0003","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2026.09.001_bib0004","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","article-title":"Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: Results from the National Cancer Data Base","volume":"63","author":"Gray","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0005","doi-asserted-by":"crossref","first-page":"456.e413","DOI":"10.1016\/j.urolonc.2023.08.003","article-title":"Analysis of treatment of muscle invasive bladder cancer using the national cancer database: Factors associated with receipt of aggressive therapy","volume":"41","author":"Moon","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0006","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0007","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: A pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0008","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.semradonc.2022.10.004","article-title":"The legacy of RTOG\/NRG protocols in shaping current bladder preservation therapy in North America","volume":"33","author":"Kamran","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/BLC-240036","article-title":"Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer","volume":"10","author":"Singh","year":"2024","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0011","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: A multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0012","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2026.09.001_bib0013","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0014","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: An updated analysis of the Massachusetts general hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2024.09.006","article-title":"Dose-escalated adaptive radiotherapy for bladder cancer: Results of the phase 2 RAIDER randomised controlled trial","author":"Huddart","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0016","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.23.02510","article-title":"Bladder-preserving trimodality treatment for high-grade T1 bladder cancer: Results from phase II protocol NRG Oncology\/RTOG 0926","volume":"42","author":"Dahl","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0017","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.23.00725","article-title":"Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer","volume":"41","author":"Swinton","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006551","article-title":"Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results from phase II study, BTCRC-GU15-023","volume":"11","author":"Joshi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clon.2019.07.017","article-title":"The intensity-modulated pelvic node and bladder radiotherapy (IMPART) trial: A phase II single-centre prospective study","volume":"32","author":"Tan","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2026.09.001_bib0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712-A randomized phase II trial","volume":"37","author":"Coen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0021","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.radonc.2016.09.006","article-title":"Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials","volume":"121","author":"Caffo","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0022","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2008.10.001","article-title":"Carbogen and nicotinamide in locally advanced bladder cancer: Early results of a phase-III randomized trial","volume":"91","author":"Hoskin","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0023","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.clon.2023.05.002","article-title":"Acute toxicity of hypofractionated and conventionally fractionated (chemo)radiotherapy regimens for bladder cancer: An exploratory analysis from the RAIDER trial","volume":"35","author":"Huddart","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2026.09.001_bib0024","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","article-title":"Long-term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-year update of the BCON (bladder carbogen nicotinamide) phase 3 randomized trial (ISRCTN45938399)","volume":"110","author":"Song","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0025","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.euo.2023.03.004","article-title":"Radiation-based therapy for muscle-invasive bladder cancer: Contemporary outcomes across tertiary centers","volume":"6","author":"Kool","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0026","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.euo.2024.01.014","article-title":"Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: An inverse probability treatment weighted analysis","volume":"7","author":"Kool","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0027","doi-asserted-by":"crossref","first-page":"893","DOI":"10.4143\/crt.2024.015","article-title":"Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder: Post hoc analysis of two prospective studies","volume":"56","author":"Cho","year":"2024","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.prro.2026.09.001_bib0028","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2020.11.036","article-title":"Outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy followed by (chemo)radiotherapy in the BC2001 trial","volume":"79","author":"Hussain","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0029","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.clgc.2014.04.002","article-title":"Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: Effect on survival and bladder preservation","volume":"12","author":"Khaled","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0030","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/bjc.2015.109","article-title":"Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder","volume":"112","author":"Hafeez","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0031","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5489\/cuaj.6459","article-title":"Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer","volume":"14","author":"Ajib","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.prro.2026.09.001_bib0032","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.urology.2012.07.045","article-title":"Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: Neoadjuvant chemotherapy and concurrent radio-chemotherapy","volume":"80","author":"Zapatero","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.prro.2026.09.001_bib0033","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2024.08.036","article-title":"Effect of complete transurethral resection on oncologic outcomes after radiation therapy for muscle-invasive bladder cancer","volume":"121","author":"Avolio","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0034","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urology.2018.07.058","article-title":"Long-term outcomes and patterns of failure following trimodality treatment with bladder preservation for invasive bladder cancer","volume":"124","author":"B\u00fcchser","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.prro.2026.09.001_bib0035","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1016\/j.clon.2022.05.003","article-title":"Mapping local failure following bladder radiotherapy according to dose","volume":"34","author":"Abdel-Aty","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2026.09.001_bib0036","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2013.52.4785","article-title":"Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: Pathologic, radiologic, and biomarker correlates","volume":"32","author":"Choueiri","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0037","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","article-title":"Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: Results of a multicenter phase II study with molecular correlates of response and toxicity","volume":"32","author":"Plimack","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109584","article-title":"Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: A nationwide cohort study","volume":"183","author":"de Haar-Holleman","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0039","first-page":"1201","article-title":"The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: A single-arm phase II study","volume":"52","author":"Kobayashi","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","article-title":"Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy","volume":"72","author":"Krasnow","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0041","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/JU.0000000000004160","article-title":"The impact of histologic subtypes on clinical outcomes after radiation-based therapy for muscle-invasive bladder cancer","volume":"212","author":"Halstuch","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0042","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.radonc.2018.05.022","article-title":"Outcomes of radiosensitisation in elderly patients with advanced bladder cancer","volume":"129","author":"Christodoulou","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0043","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.prro.2026.09.001_bib0044","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","article-title":"Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy","volume":"73","author":"Kaufman","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.prro.2026.09.001_bib0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1200\/JCO.2010.31.5721","article-title":"Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer","volume":"29","author":"Choudhury","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0046","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0047","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijrobp.2023.05.013","article-title":"Efficacy and safety of bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: Interim analysis from a multicenter, open-label, prospective phase 2 trial","volume":"117","author":"Kimura","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0048","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2024.08.007","article-title":"Long-term results of bladder preservation with twice-daily radiation plus 5-fluorouracil\/cisplatin or daily radiation plus gemcitabine for muscle-invasive bladder cancer-updated report of NRG\/RTOG 0712: A randomized phase 2 Trial","volume":"121","author":"Coen","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0049","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2016.12.018","article-title":"A phase 1\/2 trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation after transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer (Trial NRG Oncology RTOG 0524)","volume":"97","author":"Michaelson","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0050","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"Mitin","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0051","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.juro.2018.05.162","article-title":"Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: A systematic review and meta-analysis","volume":"201","author":"Kimura","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0052","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1002\/cncr.25202","article-title":"Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma","volume":"116","author":"Umbreit","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0053","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1159\/000531080","article-title":"The influence of preoperative hydronephrosis on the prognosis after radical cystectomy among patients with different pathological stages of bladder cancer","volume":"107","author":"Du","year":"2023","journal-title":"Urol Int"},{"key":"10.1016\/j.prro.2026.09.001_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222223","article-title":"Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: A meta-analysis","volume":"14","author":"Zhu","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.prro.2026.09.001_bib0055","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0056","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MOU.0000000000001090","article-title":"PET in bladder cancer imaging","volume":"33","author":"Muin","year":"2023","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0057","first-page":"30","article-title":"Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database","volume":"26","author":"Janopaul-Naylor","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0058","article-title":"Treatment approaches for non-metastatic small cell bladder cancer: A meta-analysis of reconstructed Kaplan-Meier curves","volume":"55","author":"Mose","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0059","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euo.2023.05.013","article-title":"Long-term outcomes of chemoradiation for muscle-invasive bladder cancer in noncystectomy candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1\/2 trial of Paclitaxel + Trastuzumab with daily radiation or paclitaxel alone with daily irradiation","volume":"7","author":"Dahl","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/2278-0513.148941","article-title":"Feasibility of organ preservation in muscle-invasive transitional cell carcinoma bladder: A single institutional approach","volume":"4","author":"Roy","year":"2015","journal-title":"Clin Cancer Investig J"},{"key":"10.1016\/j.prro.2026.09.001_bib0061","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/annonc\/mdu209","article-title":"Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and\/or in patients ineligible for surgery: A phase I trial","volume":"25","author":"De Santis","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0062","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.canrad.2017.09.013","article-title":"Trimodalities for bladder cancer in elderly: Transurethral resection, hypofractionated radiotherapy and gemcitabine","volume":"22","author":"Mohamed","year":"2018","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.prro.2026.09.001_bib0063","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.radonc.2020.07.057","article-title":"Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil","volume":"150","author":"Voskuilen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0064","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euo.2023.09.011","article-title":"Pembrolizumab with chemoradiation as treatment for muscle-invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase 2 clinical trial (ANZUP 1502)","volume":"7","author":"Weickhardt","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0065","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.ijrobp.2023.11.024","article-title":"Phase II trial of concurrent nivolumab and radiation therapy for muscle-invasive bladder cancer of older or chemotherapy-ineligible patients","volume":"118","author":"Vaishampayan","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0066","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2018.04.070","article-title":"Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer","volume":"101","author":"Tree","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0067","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2020.12.033","article-title":"Phase 1 trial of atezolizumab plus trimodal therapy in patients with localized muscle-invasive bladder cancer","volume":"110","author":"Marcq","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0069","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.euros.2025.11.005","article-title":"Neoadjuvant chemotherapy prior to trimodality therapy for muscle-invasive bladder cancer: A systematic review and meta-analysis","volume":"83","author":"Miyajima","year":"2026","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.prro.2026.09.001_bib0070","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"issue":"7_suppl","key":"10.1016\/j.prro.2026.09.001_bib0071","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630","article-title":"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study","volume":"44","author":"Galsky","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0072","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0073","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0074","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0075","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2026.09.001_bib0076","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.prro.2026.09.001_bib0077","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1158\/1078-0432.CCR-25-3712","article-title":"ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer","volume":"32","author":"Epstein","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.prro.2026.09.001_bib0078","first-page":"17","article-title":"Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation","volume":"18","author":"Riveros","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.prro.2026.09.001_bib0079","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.23.02718","article-title":"Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: An inverse probability treatment weighted analysis","volume":"43","author":"Marcq","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0080","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1016\/j.clon.2022.05.017","article-title":"Optimisation of radiation therapy in bladder preservation therapy for patients with clinical stage T2N0M0 bladder cancer","volume":"34","author":"Nakata","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2026.09.001_bib0081","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: An individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0082","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s13566-017-0319-2","article-title":"Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: The impact of radiotherapy dose escalation","volume":"6","author":"Korpics","year":"2017","journal-title":"J Radiat Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0083","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2015.09.010","article-title":"Clinical outcomes with dose-escalated adaptive radiation therapy for urinary bladder cancer: A prospective study","volume":"94","author":"Murthy","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0084","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clon.2019.06.005","article-title":"Adaptive radiotherapy for carcinoma of the urinary bladder: Long-term outcomes with dose escalation","volume":"31","author":"Murthy","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2026.09.001_bib0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13014-016-0618-6","article-title":"Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients","volume":"11","author":"Lutkenhaus","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0086","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3109\/0284186X.2014.928418","article-title":"A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer","volume":"53","author":"S\u00f8ndergaard","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0087","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.radonc.2012.08.011","article-title":"High precision bladder cancer irradiation by integrating a library planning procedure of 6 prospectively generated SIB IMRT plans with image guidance using lipiodol markers","volume":"105","author":"Meijer","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0088","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijrobp.2017.01.239","article-title":"Clinical outcomes of image guided adaptive hypofractionated weekly radiation therapy for bladder cancer in patients unsuitable for radical treatment","volume":"98","author":"Hafeez","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2 Suppl","key":"10.1016\/j.prro.2026.09.001_bib0089","doi-asserted-by":"crossref","first-page":"e596","DOI":"10.1016\/j.ijrobp.2024.07.1314","article-title":"Characterizing failure after trimodality therapy in bladder cancer: A retrospective analysis of clinical, spatial and dosimetric factors","volume":"120","author":"Whitmill","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0090","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/j.prro.2022.06.001","article-title":"The rate of prostatic involvement in men treated with radical cystectomy for muscle invasive bladder cancer","volume":"13","author":"Royal-Preyra","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0091","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"Kaufman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.prro.2026.09.001_bib0092","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","article-title":"RTOG 97-06: Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy","volume":"57","author":"Hagan","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0093","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijrobp.2024.07.2317","article-title":"Bladder tumor-focused adaptive radiation therapy: Clinical outcomes of a phase I dose escalation study","volume":"121","author":"Hafeez","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0094","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/1533034617691409","article-title":"Incidental dose to pelvic nodes in bladder-only radiotherapy: Is it clinically relevant?","volume":"16","author":"Lewis","year":"2017","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.prro.2026.09.001_bib0095","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.ijrobp.2011.05.051","article-title":"Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: Single-institution experience","volume":"82","author":"Tunio","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0096","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.ijrobp.2021.08.016","article-title":"Expression of Editorial Concern: Tunio MA, Hashmi A, Qayyum A, et al. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: Single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82:e457-e462","volume":"111","author":"Zietman","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0097","doi-asserted-by":"crossref","first-page":"325.e315","DOI":"10.1016\/j.urolonc.2022.12.011","article-title":"Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer","volume":"41","author":"Patel","year":"2023","journal-title":"Urol Oncol"},{"issue":"6_suppl","key":"10.1016\/j.prro.2026.09.001_bib0098","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS586","article-title":"INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer\u2014SWOG\/NRG1806","volume":"38","author":"Singh","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0099","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijrobp.2012.03.061","article-title":"Bladder cancer patterns of pelvic failure: Implications for adjuvant radiation therapy","volume":"85","author":"Baumann","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with Bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0101","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2025.03.018","article-title":"Online adaptive radiation therapy for bladder preservation: Transitioning to hypofractionation","volume":"122","author":"Krishnan","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0102","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13014-023-02348-8","article-title":"Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers","volume":"18","author":"Azzarouali","year":"2023","journal-title":"Radiat Oncol"},{"issue":"1 suppl","key":"10.1016\/j.prro.2026.09.001_bib0103","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.ijrobp.2025.06.3321","article-title":"Hypofractionated online adaptive radiotherapy for a personalized approach to muscle invasive bladder cancer","volume":"123","author":"Chiodo","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0104","article-title":"Implementation of cone beam computed tomography-guided online adaptive radiotherapy for challenging trimodal therapy in bladder preservation: A report of two cases","volume":"16","author":"Jain","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.prro.2026.09.001_bib0105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijrobp.2021.08.008","article-title":"Long-Term Outcomes of NRG Oncology\/RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in anal canal cancer","volume":"112","author":"Kachnic","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0106","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.19.02381","article-title":"Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: A report from the NRG oncology RTOG 1203 study","volume":"38","author":"Yeung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0107","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2009.12.002","article-title":"Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis","volume":"57","author":"Ramani","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0108","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.urology.2020.09.014","article-title":"Feasibility and outcomes of orthotopic Ileal neobladder reconstruction following pelvic irradiation","volume":"148","author":"Vassantachart","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.prro.2026.09.001_bib0109","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.radonc.2004.11.003","article-title":"A randomised trial of accelerated radiotherapy for localised invasive bladder cancer","volume":"75","author":"Horwich","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0110","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijrobp.2004.06.249","article-title":"Organ preservation in invasive bladder cancer: Brachytherapy, an alternative to cystectomy and combined modality treatment?","volume":"61","author":"Pos","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0111","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1093\/annonc\/mds126","article-title":"Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors","volume":"23","author":"Koning","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0112","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0360-3016(02)02739-6","article-title":"Saving bladders with brachytherapy: Implantation technique and results","volume":"53","author":"Van der Steen-Banasik","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0113","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.radonc.2009.04.020","article-title":"Brachytherapy versus cystectomy in solitary bladder cancer: A case control, multicentre, East-Netherlands study","volume":"93","author":"van der Steen-Banasik","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0114","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.radonc.2019.09.026","article-title":"Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer","volume":"141","author":"Voskuilen","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jjco\/hyw151","article-title":"Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer","volume":"47","author":"Takaoka","year":"2017","journal-title":"Jpn J Clin Oncol"},{"issue":"Suppl_1","key":"10.1016\/j.prro.2026.09.001_bib0116","doi-asserted-by":"crossref","first-page":"i49","DOI":"10.1093\/jrr\/rrad027","article-title":"Proton beam therapy for muscle-invasive bladder cancer: A systematic review and analysis with Proton-Net, a multicenter prospective patient registry database","volume":"64","author":"Araya","year":"2023","journal-title":"J Radiat Res"},{"key":"10.1016\/j.prro.2026.09.001_bib0117","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijrobp.2024.09.040","article-title":"Bladder adjuvant radiation therapy (BART): Acute and late toxicity from a phase III multicenter randomized controlled trial","volume":"121","author":"Murthy","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0118","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.euf.2021.11.004","article-title":"Adjuvant radiotherapy after radical cystectomy for patients with high-risk muscle-invasive bladder cancer: Results of a multicentric phase II trial","volume":"8","author":"Fonteyne","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.prro.2026.09.001_bib0119","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ijrobp.2024.05.012","article-title":"The value and safety of adjuvant radiation therapy after radical cystectomy in locally advanced urothelial bladder cancer: A controlled randomized study","volume":"120","author":"Zaghloul","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2017.4591","article-title":"Adjuvant sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy alone for locally advanced bladder cancer after radical cystectomy: A randomized phase 2 trial","volume":"153","author":"Zaghloul","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.prro.2026.09.001_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.01.015","article-title":"Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy","volume":"39","author":"Murthy","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0122","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ijrobp.2015.10.051","article-title":"Patterns of failure after radical cystectomy for pT3-4 bladder cancer: Implications for adjuvant radiation therapy","volume":"94","author":"Reddy","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0123","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/jso.27525","article-title":"Squamous cell carcinoma of the bladder: Demographics and outcomes associated with surgery and radiotherapy","volume":"129","author":"Larkins","year":"2024","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0124","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.juro.2010.02.021","article-title":"Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: A multicenter study of more than 4,400 patients","volume":"183","author":"Novara","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.56434\/j.arch.esp.urol.20237606.50","article-title":"Cox regression analysis of prognostic factors of intensity-modulated radiotherapy in patients with bladder cancer","volume":"76","author":"Su","year":"2023","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0126","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/cncr.28544","article-title":"Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710","volume":"120","author":"Christodouleas","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0127","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0128","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2003.05.101","article-title":"Radical cystectomy for bladder cancer today\u2013a homogeneous series without neoadjuvant therapy","volume":"21","author":"Madersbacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00345-006-0105-z","article-title":"Long-term results of standard procedures in urology: The ileal neobladder","volume":"24","author":"Hautmann","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.juro.2006.09.027","article-title":"Defining optimal therapy for muscle invasive bladder cancer","volume":"177","author":"Herr","year":"2007","journal-title":"J Urol"},{"issue":"1 Suppl","key":"10.1016\/j.prro.2026.09.001_bib0131","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.ijrobp.2025.06.1007","article-title":"Bladder adjuvant radiotherapy (BART): Clinical outcomes from a phase III multicenter randomized controlled trial","volume":"123","author":"Murthy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0132","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1002\/cam4.2102","article-title":"Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer","volume":"8","author":"Fischer-Valuck","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.prro.2026.09.001_bib0133","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2026.09.001_bib0134","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijrobp.2012.03.007","article-title":"A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy","volume":"85","author":"Baumann","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0135","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO-25-02093","article-title":"Bladder adjuvant radiotherapy: Phase III multicenter randomized controlled trial of adjuvant radiotherapy or observation for postcystectomy muscle-invasive bladder cancer","volume":"44","author":"Murthy","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0136","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00345-015-1502-y","article-title":"Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder","volume":"33","author":"Novotny","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0137","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ijrobp.2014.04.049","article-title":"Risk prediction models of locoregional failure after radical cystectomy for urothelial carcinoma: External validation in a cohort of Korean patients","volume":"89","author":"Ku","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0138","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3346\/jkms.2010.25.6.835","article-title":"Pattern of failure in bladder cancer patients treated with radical cystectomy: Rationale for adjuvant radiotherapy","volume":"25","author":"Kim","year":"2010","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.prro.2026.09.001_bib0139","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.3390\/cancers14235740","article-title":"Oncological outcomes for patients harboring positive surgical margins following radical cystectomy for muscle-invasive bladder cancer: A retrospective multicentric study on behalf of the YAU urothelial group","volume":"14","author":"Marcq","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2026.09.001_bib0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.euo.2018.11.010","article-title":"National practice patterns and overall survival after adjuvant radiotherapy following radical cystectomy for urothelial bladder cancer in the USA, 2004-2013","volume":"3","author":"Bateni","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0141","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2147\/CMAR.S69055","article-title":"Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: Results of 170 patients","volume":"6","author":"Bayoumi","year":"2014","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.prro.2026.09.001_bib0142","doi-asserted-by":"crossref","first-page":"188.e181","DOI":"10.1016\/j.urolonc.2024.11.021","article-title":"Retrospective analysis of partial cystectomy in patients with muscle-invasive urothelial carcinoma: A German single-center experience","volume":"43","author":"Schmidt","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0143","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.clgc.2017.05.007","article-title":"Tolerance of orthotopic ileal neobladders to radiotherapy: A multi-institutional retrospective study","volume":"15","author":"Ballas","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0144","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0360-3016(92)90005-3","article-title":"Postoperative radiotherapy of carcinoma in bilharzial bladder: Improved disease free survival through improving local control","volume":"23","author":"Zaghloul","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0145","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.ijrobp.2022.07.475","article-title":"INTACT (S\/N1806): Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer\u2014toxicity update on first 213 patients","volume":"114","author":"Singh","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0146","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2026.09.001_bib0147","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2026.09.001_bib0148","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ijrobp.2016.01.034","article-title":"Validating a local failure risk stratification for use in prospective studies of adjuvant radiation therapy for bladder cancer","volume":"95","author":"Baumann","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0149","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.prro.2022.05.014","article-title":"International consensus guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy: Update from an IBIS workgroup","volume":"12","author":"Verghote","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0150","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijrobp.2016.04.032","article-title":"Development and validation of consensus contouring guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy","volume":"96","author":"Baumann","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0151","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/j.clon.2023.04.010","article-title":"Study protocol of the Bladder Adjuvant RadioTherapy (BART) trial: A randomised phase III trial of adjuvant radiotherapy following cystectomy in bladder cancer","volume":"35","author":"Murthy","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2026.09.001_bib0152","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.meddos.2015.06.001","article-title":"Adjuvant radiation therapy for bladder cancer: A dosimetric comparison of techniques","volume":"40","author":"Baumann","year":"2015","journal-title":"Med Dosim"},{"key":"10.1016\/j.prro.2026.09.001_bib0153","first-page":"181","article-title":"Hypofractionated palliative radiotherapy for bladder cancer","volume":"24","author":"Dirix","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0154","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1590\/S1677-5538.IBJU.2013.06.06","article-title":"The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery","volume":"39","author":"Lacarri\u00e8re","year":"2013","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1590\/S1677-5538.IBJU.2013.01.10","article-title":"Evaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancer","volume":"39","author":"Kouloulias","year":"2013","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.prro.2026.09.001_bib0156","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.21873\/invivo.11718","article-title":"Efficacy of palliative bladder radiotherapy for hematuria in advanced bladder cancer using contemporary radiotherapy techniques","volume":"33","author":"Tey","year":"2019","journal-title":"In Vivo"},{"key":"10.1016\/j.prro.2026.09.001_bib0157","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijrobp.2019.06.2541","article-title":"Palliative radiation therapy in bladder cancer-importance of patient selection: A retrospective multicenter study","volume":"105","author":"Ali","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0158","doi-asserted-by":"crossref","first-page":"S696","DOI":"10.1016\/j.ijrobp.2014.05.2043","article-title":"Hemostatic radiotherapy in advanced bladder cancer: A single-institution experience","volume":"90","author":"Aljabab","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0159","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3390\/cancers15041161","article-title":"Consolidative radiotherapy for metastatic urothelial bladder cancer patients with no progression and with no more than five residual metastatic Lesions following first-line systemic therapy: A retrospective analysis","volume":"15","author":"Aboudaram","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2026.09.001_bib0160","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4149\/neo_2018_180522N333","article-title":"Recurrent oligometastatic transitional cell bladder carcinoma: Is there room for radiotherapy?","volume":"66","author":"Augugliaro","year":"2019","journal-title":"Neoplasma"},{"key":"10.1016\/j.prro.2026.09.001_bib0161","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clon.2020.07.008","article-title":"Stereotactic body radiation therapy in the management of oligometastatic and oligoprogressive bladder cancer and other urothelial malignancies","volume":"33","author":"Franzese","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2026.09.001_bib0162","article-title":"Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience","volume":"19","author":"Francolini","year":"2019","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.prro.2026.09.001_bib0163","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0360-3016(00)00430-2","article-title":"A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: Results of medical research council trial BA09","volume":"47","author":"Duchesne","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0164","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.3390\/cancers16183201","article-title":"Oligometastatic urothelial cancer and stereotactic body radiotherapy: A systematic review and an updated insight of current evidence and future directions","volume":"16","author":"Angrisani","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2026.09.001_bib0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13014-024-02465-y","article-title":"Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: A single institution real-world experience","volume":"19","author":"Svedman","year":"2024","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0166","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2016.66.7352","article-title":"Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: A propensity score-weighted analysis from the National Cancer Data Base","volume":"34","author":"Seisen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0167","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.euo.2022.02.001","article-title":"Association between local radiation therapy to the primary bladder tumor and overall survival for patients with metastatic urothelial cancer receiving systemic chemotherapy","volume":"5","author":"Fischer-Valuck","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0168","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.23.00753","article-title":"Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: A multicenter, randomized phase II clinical trial","volume":"42","author":"Gillespie","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0169","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","article-title":"Radiation therapy for brain metastases: An ASTRO clinical practice guideline","volume":"12","author":"Gondi","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0170","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00066-010-2159-5","article-title":"A comparison of radiotherapy with radiotherapy plus surgery for brain metastases from urinary bladder cancer: Analysis of 62 patients","volume":"186","author":"Fokas","year":"2010","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.prro.2026.09.001_bib0171","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000488151","article-title":"Gamma knife stereotactic radiosurgery for the treatment of brain metastases from primary tumors of the urinary bladder","volume":"96","author":"Taylor","year":"2018","journal-title":"Stereotact Funct Neurosurg"},{"key":"10.1016\/j.prro.2026.09.001_bib0172","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijrobp.2009.07.1717","article-title":"Hypofractionated whole-brain radiotherapy for multiple brain metastases from transitional cell carcinoma of the bladder","volume":"78","author":"Rades","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.09.001_bib0173","doi-asserted-by":"crossref","first-page":"e995","DOI":"10.1016\/j.clgc.2019.05.008","article-title":"Racial and socioeconomic disparities in bladder cancer survival: Analysis of the California Cancer Registry","volume":"17","author":"Sung","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0174","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/cam4.4917","article-title":"Racial inequity and other social disparities in the diagnosis and management of bladder cancer","volume":"12","author":"Hasan","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.prro.2026.09.001_bib0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.urology.2020.06.087","article-title":"Sex and racial disparities in the treatment and outcomes of muscle-invasive bladder cancer","volume":"151","author":"Marinaro","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.prro.2026.09.001_bib0176","first-page":"5603","article-title":"Radical cystectomy versus chemoradiation for muscle-invasive bladder cancer: Impact of treatment facility and sociodemographics","volume":"37","author":"Haque","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.prro.2026.09.001_bib0177","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7301","article-title":"Impact of rural location on receipt of standard of care treatment and survival for locally advanced bladder cancer in Louisiana","volume":"13","author":"Escott","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.prro.2026.09.001_bib0178","first-page":"139","article-title":"Bladder cancer stage and mortality: Urban vs. rural residency","volume":"32","author":"Deuker","year":"2021","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.prro.2026.09.001_bib0179","doi-asserted-by":"crossref","first-page":"199.e115","DOI":"10.1016\/j.urolonc.2022.03.013","article-title":"An evaluation of trends in the representation of patients by age, sex, and diverse race\/ethnic groups in bladder and kidney cancer clinical trials","volume":"40","author":"Javier-DesLoges","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0180","first-page":"1071","article-title":"Race reporting and disparities regarding clinical trials in bladder cancer: A systematic review","volume":"33","author":"Freudenburg","year":"2022","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.prro.2026.09.001_bib0181","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.3390\/cancers16193338","article-title":"Meta-analysis of age, sex, and race disparities in the era of contemporary urothelial carcinoma treatment","volume":"16","author":"Barsouk","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2026.09.001_bib0182","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.urology.2023.02.045","article-title":"Insurance type and area deprivation are associated with worse overall mortality for patients with muscle-invasive bladder cancer","volume":"177","author":"Miller","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.prro.2026.09.001_bib0183","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cncr.24701","article-title":"Racial differences in treatment and outcomes among patients with early stage bladder cancer","volume":"116","author":"Hollenbeck","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0184","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2026.09.001_bib0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.23986","article-title":"Sex and racial differences in bladder cancer presentation and mortality in the US","volume":"115","author":"Scosyrev","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0186","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.urology.2011.02.042","article-title":"Ethnic differences in bladder cancer survival","volume":"78","author":"Yee","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.prro.2026.09.001_bib0187","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1158\/1055-9965.EPI-18-1280","article-title":"Social determinants of appropriate treatment for muscle-invasive bladder cancer","volume":"28","author":"Washington","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.prro.2026.09.001_bib0188","doi-asserted-by":"crossref","first-page":"456.e1","DOI":"10.1016\/j.urolonc.2023.06.020","article-title":"Racial and sex differences in tumor genomics in urothelial carcinoma","volume":"41","author":"Nyame","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0189","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/cncr.31926","article-title":"Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?","volume":"125","author":"Cole","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0190","doi-asserted-by":"crossref","first-page":"pkaf054","DOI":"10.1093\/jncics\/pkaf054","article-title":"Socioeconomic disparities and bladder cancer stage at diagnosis: A statewide cohort analysis","volume":"9","author":"Finocchiaro","year":"2025","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.prro.2026.09.001_bib0191","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/23523735241289237","article-title":"Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies","volume":"10","author":"Castellon-Lopez","year":"2024","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0192","doi-asserted-by":"crossref","first-page":"374.e11","DOI":"10.1016\/j.urolonc.2024.06.012","article-title":"Socioeconomic and demographic disparities in immunotherapy utilization for advanced kidney and bladder cancer","volume":"42","author":"Holland","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.prro.2026.09.001_bib0193","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/cam4.3835","article-title":"Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study","volume":"10","author":"Ballas","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.prro.2026.09.001_bib0194","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clgc.2017.11.004","article-title":"Contemporary patterns of multidisciplinary care in patients with muscle-invasive bladder cancer","volume":"16","author":"Harshman","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.prro.2026.09.001_bib0195","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.3390\/cancers16234100","article-title":"Sex disparities in bladder cancer diagnosis and treatment","volume":"16","author":"Pignot","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2026.09.001_bib0196","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.prro.2026.09.001_bib0197","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026002730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026002730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T12:39:56Z","timestamp":1794055196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850026002730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":196,"alternative-id":["S1879850026002730"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2026.09.001","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy for Bladder Cancer: An ASTRO Clinical Practice Guideline","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}